When comparing their follow-up period in conventional MRIs, our wild-type IDH GBM cases showed clear tumor progression by 5–7 months post-RT (Figure 6, upper and middle panels) versus the initial regression of tumor followed by the overall control of the disease for greater than two years from the completion of RT in our mutant IDH1 GBM (Figure 6, lower panel). This evidence concerns the gene IDH1 and glioblastoma.